广东深入贯彻国务院办公厅印发的《关于提升中药质量促进中医药产业高质量发展的意见》，强化以点 带面，依托广州市在医疗资源、产业基础和市场规模上的突出优势，率先开展制度创新和先行先试，为 全省积累可复制、可推广的经验，辐射带动全省制剂产业协同发展。医疗机构制剂产业发展存在多重梗 阻：生产端存在设备自动化程度低、检测精度不足、依赖人工操作易致污染；监管环节因资源有限难以 全覆盖抽检，不良反应监测体系不完善；成本方面中药材价格大幅上涨而制剂定价受限，导致"价格倒 挂"逼停部分品种。 省工业和信息化厅等七部门与广州市密切协作，依托专家团队共同破解难题，出台《关于支持广州市带 动全省医疗机构制剂产业高质量发展的若干措施》。新政围绕"研发转化提速、制造体系重构、资源蓄 水池扩容、服务能级提升、金融生态培育"五大方面，创新性地提出19条具体举措，为广东在该领域先 行先试提供制度范本。 近日，广东省在广州市召开全省医疗机构制剂产业高质量发展推进会，正式宣贯《关于支持广州市带动 全省医疗机构制剂产业高质量发展的若干措施》（粤工信规字〔2025〕7号），标志着全国首个针对医 疗机构制剂产业发展的专项政策进入全面实施阶段。这一政策是 ...

（来源：衢州日报） 转自：衢州日报 国家药监局日前公布数据：2025年我国已批准上市的创新药达76个，超过2024年的48个，创历史新高。 此外，2025年我国创新药对外授权交易总金额超过1300亿美元，授权交易数量超过150笔，同样创历史 新高。 据介绍，2025年国家药监局批准上市的76个创新药，包括47个化学药品、23个生物制品和6个中药。47 个化学药品中，38个为国产创新药，9个为进口创新药，国产创新药占比达80.85%；23个生物制品中， 21个为国产创新药，2个为进口创新药，国产创新药占比达91.30%。这些创新药获批上市，标志着我国 生物医药领域实现了从跟跑到并跑、部分领跑的跨越，说明我国已经成为全球生物医药创新领域的重要 力量。 据《人民日报》 ...

（文章来源：人民日报） 本报北京1月4日电 （记者申少铁）国家药监局日前公布数据：2025年我国已批准上市的创新药达76 个，超过2024年的48个，创历史新高。此外，2025年我国创新药对外授权交易总金额超过1300亿美元， 授权交易数量超过150笔，同样创历史新高。 据介绍，2025年国家药监局批准上市的76个创新药，包括47个化学药品、23个生物制品和6个中药。47 个化学药品中，38个为国产创新药，9个为进口创新药，国产创新药占比达80.85%；23个生物制品中， 21个为国产创新药，2个为进口创新药，国产创新药占比达91.30%。这些创新药获批上市，标志着我国 生物医药领域实现了从跟跑到并跑、部分领跑的跨越，说明我国已经成为全球生物医药创新领域的重要 力量。 ...

我国在研新药管线约占全球30%，位列全球第二。在政策红利持续释放下，近年来，上市创新药品 企业不断加大研发投入，我国自主研发的创新药"出海"成果斐然。 央广网北京1月4日消息（记者王逸群）据中央广播电视总台中国之声《新闻和报纸摘要》报道，国 家药监局数据显示，2025年我国已批准上市的创新药达76个，我国创新药对外授权交易总金额超1300亿 美元，授权交易数量超150笔，均创历史新高。 蓝恭涛：下一步将审评资源更多地向临床急需的重点品种倾斜，特别是对新机制、新靶点的创新 药，加大支持力度。进一步完善药品试验数据保护制度、药品市场独占期制度，系统强化对创新的保 护。 蓝恭涛：这些创新药在我国上市，使得我国患者可以更早获得全球生物医药创新最新成果的治疗， 标志着我国生物医药领域实现了从跟跑到并跑、部分领跑的跨越，说明我国已经成为全球生物医药创新 领域的重要力量。 2025年国家药监局批准上市的76个创新药，包括47个化学药品、23个生物制品和6个中药。47个化 学药品中，国产创新药占比达80.85%；23个生物制品中，国产创新药占比达91.30%。国家药监局药品 注册管理司副司长蓝恭涛介绍，2025年我国批准的首 ...

Core Insights - In 2025, China approved a record 76 innovative drugs, significantly surpassing the 48 approved in 2024, marking a historical high [1] - The total value of innovative drug licensing transactions in 2025 exceeded $130 billion, with over 150 transactions, also a historical high [2] - The increase in innovative drug approvals and licensing reflects China's progress in drug evaluation reforms and the international recognition of the value of its innovative drugs [2] Summary by Sections Innovative Drug Approvals - In 2025, 76 innovative drugs were approved, including 47 chemical drugs, 23 biological products, and 6 traditional Chinese medicines [1] - Among the 47 chemical drugs, 38 were domestically developed, representing 80.85% of the total [1] - For the 23 biological products, 21 were domestically developed, accounting for 91.30% [1] - 11 first-in-class innovative drugs were approved, with 4 being independently developed in China [1] Licensing Transactions - The total licensing transaction amount for innovative drugs in 2025 was over $130 billion, nearly doubling from $51.9 billion in 2024 [2] - The number of licensing transactions increased to over 150, compared to 94 in 2024 [2] - China's pipeline of new drugs accounts for approximately 30% of the global total, ranking second worldwide [2] Future Initiatives - Starting in 2026, the National Medical Products Administration (NMPA) will implement more measures to accelerate the development of innovative drugs [3] - There will be a focus on prioritizing review resources for urgently needed clinical products, especially those with new mechanisms and targets [3] - The NMPA plans to enhance support through breakthrough therapy designations, conditional approvals, and priority reviews to expedite the market entry of critical drugs [3]

成都医学城 转自：新华财经 12月10日，成都药康生命科学研发生产二期项目投产仪式在成都医学城举行。该项目将进一步巩固成都药康在遗传工程领域的核心优势，增强医药创新"源 头"支撑，在更好赋能和加速西部创新药企发展的同时，为成都医学城建强CXO（医药研发生产外包服务组织）赛道提供新助力。 成都药康生物科技有限公 成都药康生物科技有限公司（以下简称"成都药康"）系江苏集萃药康生物科技股份有限公司（以下简称"药康生物"）的全资子公司，2018年8月落地成都温 江，一期项目于2020年11月获批生产许可，业务以"基因编辑模型+药效筛选"为核心，为创新药企提供"源头"服务，提高药物筛选成功率。 成都药康生物科技有限公司 活动现场，成都医学院与成都药康签订战略合作协议，并为双方共建的"衰老机制与干预四川省重点实验室"揭牌。根据协议，成都药康将发挥在模式动物研 发、疾病模型创制及产业化应用领域的领先优势，整合成都医学院在医学教育、科学研究及临床资源方面的优势，共同推动区域生物医药产业高质量发展， 培养高层次应用型人才，加速科研成果转化。 作为成都市发展创新药的主阵地，10余年来，成都医学城深耕生物医药产业，目前已聚集科伦博 ...

Core Insights - Bayer has officially launched its Open Innovation Center in the International Pharmaceutical Innovation Park in Beijing, marking a significant step in fostering local pharmaceutical innovation and collaboration with high-level research institutions [1][2] - The park aims to incubate local innovative pharmaceutical companies and facilitate their global expansion, aligning with China's strategic focus on developing innovative drugs and medical devices [1][3] Group 1: Development and Infrastructure - The International Pharmaceutical Innovation Park covers an area of 5.8 square kilometers and is divided into four functional zones: headquarters cluster, medical-engineering integration area, R&D transformation area, and pharmaceutical manufacturing area [2][3] - The park has a built-up area of 280,000 square meters, with ongoing construction of supporting facilities for pharmaceutical R&D [2] Group 2: Industry Collaboration and Growth - The park is attracting major international pharmaceutical companies, including AstraZeneca and Medtronic, with 12 global pharmaceutical giants expected to establish operations [2][3] - The park is leveraging Beijing's policy, innovation, and openness advantages to create a preliminary agglomeration of the biopharmaceutical industry, with plans for more leading innovative drug and device companies to settle by 2026 [3] Group 3: Future Directions and Innovations - The park is set to develop an AI healthcare industry cluster, focusing on AI applications in pharmaceutical manufacturing and precision diagnosis [3] - A comprehensive ecosystem is being constructed, integrating industry chains, innovation chains, talent chains, and ecological chains to support the entire lifecycle of product development from R&D to large-scale production [3]

Group 1 - The rapid development of China's biopharmaceutical sector has attracted significant foreign investment, with Gattefossé celebrating 20 years in the Chinese market and expanding its technical center in Shanghai by over 60% [1] - Gattefossé's CEO highlighted that Asia accounts for nearly 25% of the group's revenue, with China playing a crucial role in this growth [1] - Over the past two decades, China has transformed from a follower to a leader in the pharmaceutical and personal care sectors, driving continuous innovation [1] Group 2 - Gattefossé's China General Manager noted that nearly 30% of new drug molecules originate from Chinese research, reflecting the country's strategic shift towards original small molecules, peptides, and biopharmaceuticals [2] - The company has observed significant global recognition of leading CDMOs and emerging biotech firms in China, which have attracted billions in venture capital [2] - Gattefossé is committed to deepening collaborations with local partners and universities, recognizing the immense potential in the Chinese market [2] Group 3 - The company aims to keep pace with China's rapid innovation and respond to local customer needs, viewing the future in China with optimism [2] - Gattefossé plans to increase investments, strengthen local teams, and create new job opportunities in China, demonstrating a long-term commitment to the market [2]

Core Insights - The Zhongguancun Life Science Park has transformed into a vital axis for Beijing's international technology innovation center, evolving from rural areas into a hub for life sciences and biotechnology [1][3] - The park is home to over 600 innovative pharmaceutical companies, creating a vibrant ecosystem that includes leading enterprises, innovative SMEs, supportive policies, and capital [1][2] Group 1: Innovation Ecosystem - The park features a comprehensive innovation chain that encompasses basic research, technology development, clinical validation, and production [2][3] - Key institutions such as the National Protein Science Center and various top-tier research institutes are located within the park, facilitating significant advancements in life sciences [2][3] - The park has produced notable innovations, including China's first billion-dollar drug and several cutting-edge gene editing tools recognized internationally [3][4] Group 2: Entrepreneurial Environment - The park has become a "paradise for scientists" where many researchers have founded their own companies, with 112 enterprises established by scientists [5][6] - Early support for scientific entrepreneurship is a unique attraction of the park, providing essential resources and funding for startups [6][7] - The park's strong industry cluster effect allows scientists to easily find partners and resources, significantly lowering the barriers to entrepreneurship [7][8] Group 3: Financial Support and Investment - The Beijing government has established a 20 billion yuan investment fund to support the pharmaceutical and health industry, ensuring financial backing for innovation [7][8] - The park's management has created a multi-layered investment fund matrix, collaborating with over 50 market-oriented investment funds to empower original innovations [8][9] Group 4: Future Development - The park aims to maintain its leading position in emerging fields such as cell and gene therapy, with ongoing projects and clinical trials [3][9] - The construction of third-party service platforms and technology centers is crucial for accelerating innovation and enhancing industry competitiveness [9][10] - The park is focused on expanding its global influence in the biopharmaceutical sector, with a commitment to fostering original discoveries that benefit the world [12]

Core Insights - Eli Lilly announced the official launch of its Shanghai Innovation Incubator (Lilly Gateway Labs, LGL) during the "2025 Lilly China Science Day" forum, marking its second incubator in China after Beijing [2] - The incubator has signed its first resident company, Molecular Heart, and established strategic partnerships with three local firms: Saintin Biotech, Insilico Medicine, and Suzhou Almai Biotechnology, aiming to accelerate the market entry of breakthrough therapies [2][3] - The Shanghai incubator is designed to accommodate 8 to 10 high-potential biotech companies and around 100 research talents, providing top-tier laboratory space and access to Eli Lilly's network of scientists and executives [3] Company Strategy - Eli Lilly's establishment of the Shanghai incubator is part of a broader strategy to enhance its external innovation framework in China, which includes venture capital, innovation cooperation centers, and incubators [2][4] - The company aims to leverage its international experience and global network to optimize the biopharmaceutical ecosystem in Shanghai, contributing to the city's goal of becoming a world-class biopharmaceutical industry cluster [3][4] - Eli Lilly has been actively collaborating with local enterprises since 2008, establishing a comprehensive external innovation matrix that spans the entire drug development cycle from target discovery to commercialization [4]